REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027 Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE® and ASCENT®, expected in Q4 2026 Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoing...
Covered in this story
Analyst targets on Advanced Micro Devices
- TD Cowen: $538 → $675 by Oct 2027 · Buy via Investing.com India
- Bank of America: $606 → $720 by Oct 2027 · Buy via FXLeaders
- Mizuho: $649 → $705 by Oct 2027 · outperform via FXLeaders
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Advanced Micro Devices →Dalsna Finance is currently tracking 57 stories mentioning Advanced Micro Devices, the earliest published 11 Oct 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.